Vertex Pharmaceuticals Inc (VRTX.OQ) Quote| Reuters.com
Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

81.90USD
24 Jun 2016
Change (% chg)

$-6.30 (-7.14%)
Prev Close
$88.20
Open
$83.58
Day's High
$85.68
Day's Low
$81.82
Volume
839,829
Avg. Vol
679,058
52-wk High
$143.20
52-wk Low
$75.92

VRTX.OQ

Chart for VRTX.OQ

About

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $20,257.95
Shares Outstanding(Mil.): 247.35
Dividend: --
Yield (%): --

Financials

  VRTX.OQ Industry Sector
P/E (TTM): -- 38.82 34.11
EPS (TTM): -1.65 -- --
ROI: -23.52 -5.72 14.23
ROE: -41.31 -4.83 15.46

BRIEF-Spero Therapeutics to acquire worldwide rights to Vertex's VXC-486/VXC-100

* Deal to acquire worldwide rights to VXC-486/VXC-100 and a portfolio of innovative antibacterial compounds

May 25 2016

BRIEF-Paulson & Co takes stake in Activision Blizzard

* Paulson & Co Takes Share Stake Of 3.1 Mln Shares In Activision Blizzard Inc - Sec filing

May 16 2016

BRIEF-Vertex Pharmaceuticals files for potential mixed shelf

* Files for potential mixed shelf; size not disclosed - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 03 2016

BRIEF-Vertex reports Q1 GAAP loss per share $0.17 including items

* Q1 earnings per share view $0.29 -- Thomson Reuters I/B/E/S

Apr 27 2016

UK cost agency says "no" to pricey Vertex cystic fibrosis drug

LONDON, March 23 A new cystic fibrosis treatment from Vertex Pharmaceuticals has been rejected as too expensive by Britain's healthcare cost agency NICE.

Mar 22 2016

FDA rejects expanded use of Vertex's cystic fibrosis drug

The U.S. Food and Drug Administration has denied the expanded use of Vertex Pharmaceutical Inc's bestseller, Kalydeco, in certain cystic fibrosis patients, the company said on Friday.

Feb 05 2016

CORRECTED-FDA rejects expanded use of Vertex's cystic fibrosis drug

Feb 5 The U.S. Food and Drug Administration has denied the expanded use of Vertex Pharmaceutical Inc's bestseller, Kalydeco, in certain cystic fibrosis patients, the company said on Friday.

Feb 05 2016

UPDATE 2-FDA rejects expanded use of Vertex cystic fibrosis drug

* Amounts to deferral of about $300 mln in U.S. revenue - analyst

Feb 05 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.